Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial

RATIONALE: The cystic fibrosis (CF) modulator drug, elexacaftor/tezacaftor/ivacaftor (ETI), proved highly effective in controlled clinical trials for individuals with at least one F508del allele, which occurs in at least 85% of people with CF. OBJECTIVES: PROMISE is a postapproval study to understan...

Descripción completa

Detalles Bibliográficos
Autores principales: Nichols, David P., Paynter, Alex C., Heltshe, Sonya L., Donaldson, Scott H., Frederick, Carla A., Freedman, Steven D., Gelfond, Daniel, Hoffman, Lucas R., Kelly, Andrea, Narkewicz, Michael R., Pittman, Jessica E., Ratjen, Felix, Rosenfeld, Margaret, Sagel, Scott D., Schwarzenberg, Sarah Jane, Singh, Pradeep K., Solomon, George M., Stalvey, Michael S., Clancy, John P., Kirby, Shannon, Van Dalfsen, Jill M., Kloster, Margaret H., Rowe, Steven M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Thoracic Society 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8906485/
https://www.ncbi.nlm.nih.gov/pubmed/34784492
http://dx.doi.org/10.1164/rccm.202108-1986OC

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8906485/
https://www.ncbi.nlm.nih.gov/pubmed/34784492
http://dx.doi.org/10.1164/rccm.202108-1986OC

Ejemplares similares